Sciencast Management LP Raises Stock Holdings in Hologic, Inc. $HOLX

Key Points

• Sciencast Management LP significantly increased its holdings in Hologic, Inc. by 245.2% in Q1, acquiring a total of 33,242 shares valued at approximately $2.05 million.
• Multiple hedge funds have also initiated or expanded their positions in Hologic, indicating a high level of institutional interest, with about 94.73% of the company's stock owned by institutional investors.
• Research analysts set new price targets for Hologic shares, with a consensus target price of $78.00 and several firms upgrading their ratings to "buy," suggesting positive market sentiment.

Sciencast Management LP increased its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 245.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,242 shares of the medical equipment provider's stock after acquiring an additional 23,612 shares during the period. Sciencast Management LP's holdings in Hologic were worth $2,053,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Zions Bancorporation National Association UT purchased a new position in Hologic in the 1st quarter worth $34,000. Allworth Financial LP grew its position in Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after purchasing an additional 216 shares during the period. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Hologic during the 1st quarter worth about $42,000. Larson Financial Group LLC grew its position in Hologic by 6,016.7% during the 1st quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock worth $45,000 after purchasing an additional 722 shares during the period. Finally, Raiffeisen Bank International AG acquired a new stake in Hologic during the 4th quarter worth about $49,000. Hedge funds and other institutional investors own 94.73% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on HOLX shares. Mizuho set a $75.00 price target on shares of Hologic in a research note on Thursday, July 31st. Needham & Company LLC reissued a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Wall Street Zen raised shares of Hologic from a "hold" rating to a "buy" rating in a research note on Sunday. Citigroup raised shares of Hologic from a "neutral" rating to a "buy" rating and raised their target price for the stock from $60.00 to $80.00 in a research note on Wednesday, July 9th. Finally, Morgan Stanley increased their price target on Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a research report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $78.00.

Hologic Trading Up 0.6%

NASDAQ:HOLX opened at $66.76 on Monday. The stock's 50 day moving average price is $66.34 and its 200 day moving average price is $62.59. The company has a market capitalization of $14.85 billion, a PE ratio of 27.70, a P/E/G ratio of 2.42 and a beta of 0.57. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm's quarterly revenue was up 1.2% compared to the same quarter last year. During the same quarter last year, the business posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.